AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

S. Hong, David; Kurzrock, Razelle; Kim, Youngsoo; Woessner, Richard; Younes, Anas; Nemunaitis, John; Fowler, Nathan; Zhou, Tianyuan; Schmidt, Joanna; Jo, Minji; J. Lee, Samantha; Yamashita, Mason; G. Hughes, Steven; Fayad, Luis; A. Piha‐Paul, Sarina; V.P. Nadella, Murali; Mohseni, Morvarid; Lawson, Deborah; Reimer, Corinne; C. Blakey, David; Xiao, Xiaokun; Hsu, Jeff; S. Revenko, Alexey; P. Monia, Brett; Robert MacLeod, A.

doi:10.1126/scitranslmed.aac5272

Public

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Published in Science Translational Medicine • Nov 18, 2015

Authors:

David S. Hong

Razelle Kurzrock

Youngsoo Kim

Abstract

Next-generation sequencing technologies have greatly expanded our understanding of cancer genetics. Antisense technology is an attractive platform with the potential to translate these advances into improved cancer therapeutics, because antisense oligonucleotide (ASO) inhibitors can be designed on t...

Subject

Lung cancer

Oligonucleotide

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!